Key facts
- It has raised $200K; the latest was Later Stage VC in Nov 2025.
- Notable investors include US National Science Foundation, Berkeley SkyDeck, ZAKA VC, Illumina Ventures, Berkeley SkyDeck Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for DeepSeq.AI
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepSeq.AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepSeq.AI
Developer of a protein engineering platform designed to transform the proteomics process with a screening strategy. The company's platform utilizes artificial intelligence and machine learning to cluster and search similar proteins based on their physical properties, predict potential interactions, and create synthetic sequences, enabling researchers to develop drugs in smart and efficient ways.
- Sector
- Healthcare
- HQ
- Sacramento, CA, United States
- Founded
- 2019
- Employees
- 3
- Website
- deepseq.ai/
- Ownership
- Privately Held (backing)
DeepSeq.AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepSeq.AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepSeq.AI in its N-PORT filings yet. We sweep new filings monthly.